SENSEX NIFTY

Taro

May 02, 2016 at 13:18 | Source: CNBC
The Nikkei 225 closed down 518.67 points, or 3.11 percent, at 16,147.38, after initially tumbling as much as 4.14 percent in early trade. On Thursday, the benchmark index shed 3.61 percent, after the Bank of Japan surprised markets by standing pat on its monetary policy.
May 02, 2016 at 10:26 | Source: Reuters
Adding to the subdued sentiment, a survey released on Sunday showed that activity in China's manufacturing sector expanded for the second month in a row in April but only marginally, raising doubts about the sustainability of a recent pick-up in the economy.
Apr 29, 2016 at 08:01 | Source: CNBC
Australia's ASX 200 was down 0.21 percent after the open, with declines in the heavily-weighted financials sub-index and the materials sub-index. In South Korea, the Kospi was down 0.37 percent.
Apr 28, 2016 at 11:35 | Source: CNBC
The benchmark Nikkei 225 was down 3.24 percent, compared to a 1.41 percent gain before the decision. The Topix index fell 2.15 percent.
Apr 28, 2016 at 08:10 | Source: CNBC
In Japan, the Nikkei 225 advanced 1.03 percent, while across the Korean Strait, the Kospi wavered between positive and negative territory before trading down 0.19 percent.
Apr 15, 2016 at 08:41 | Source: Reuters
Japan's Nikkei was down 0.3 percent, while Australian shared edged up 0.4 percent. Other modest gainers included Malaysian and Indonesian stocks.
Apr 13, 2016 at 07:49 | Source: CNBC
Australia's ASX 200 was up 1.18 percent in early trade, boosted by advances in the heavily-weighted financials subindex, up 1.07 percent. The energy and materials subindexes were also up 2.81 and 2.76 percent respectively.
Apr 11, 2016 at 07:45 | Source: CNBC
Australia's ASX 200 was off 0.25 percent, weighed by a 0.48 percent decline in the heavily-weighted financials subindex. The energy subindex advanced 1.51 percent, while the materials subindex was up 0.63 percent.
Apr 08, 2016 at 07:55 | Source: Reuters
MSCI's broadest index of Asia-Pacific shares outside Japan fell 0.5 percent while Japan's Nikkei dropped 1.4 percent to near-two-month lows, with financials coming under pressure.
Messages on Taro »

maximindia

Platinum Member

673 Followers

Ranbaxy Labs  

One must understand that SUN cannot b redflagged bcs its main subsidiary is TARO is situated in Iserael which has more strintest practoces more than even USA.Also USA realised that by redflagging Indian cos like RBaxy it is USA public which is suffering bcs of nongen drugs produced by another

6.26 PM Jul 7th 2014

shmarketgen
ius

Platinum Member

736 Followers

Suven Life Scie  

That`s also a good strategy.Something I hear/read,even RJ follows.SLS management is conservative & Mr. Jasti has always been very candid about his company.Recently,they had achieved aprroval for Malathion,to be marketed by Taro.The bottomline will be 2MUSD every year from this product alone! See

9.23 PM Jul 3rd 2014

2sunilkamat
h

Silver Member

16 Followers

Sun Pharma  

Ultimately patience is paying rich dividends. Good to know Taro has shot up by more than 16%. Sun should open with a big gap monday morning. Cheers!

8.49 PM Jun 28th 2014

anky51

Gold Member

23 Followers

Sun Pharma  

Awsome Taro....16% up at 137 !! good news coming for sun pharma as well !!

6.53 PM Jun 28th 2014

yuvaraj1972

Gold Member

18 Followers

Sun Pharma  

dear kurken...its other way buddy they will acquire mnc`s like taro,caraco,dusa etc...list not going to stop and its a professionally managed company...stay invested...

10.27 AM May 30th 2014

future_call
s

New Member

147 Followers

Lupin  

Guys: Hope you got benefitted by my buy call on Lupin today... all the pharma stocks buzzing Dr. Reddy, Lupin, Div lab... tomorrow sun pharma likely to post good results.. so continue buy Lupin as near term target is 960. Strong results of Taro is set to boost Sun Pharma`s Q4FY2014 results. Taro

4.06 PM May 28th 2014

future_call
s

New Member

147 Followers

Sun Pharmaceutical Industries  

Strong results of Taro is set to boost Sun Pharma`s Q4FY2014 results. Taro Pharma contributes near 48% of US revenue and 29% of total revenue. Sharekhan expect Sun Pharma to report a revenue of Rs4290 crore (39.7% YoY)and net profit of Rs1313 crore (29.8% YoY) in Q4FY2014. Sharekhan can expect

4.03 PM May 28th 2014

Sun Pharma  

Taro EPS up 44% for FY.

2.43 PM May 28th 2014

Sun Pharma  

Net income attributable to Taro was $360.4 million compared to $266.2 million, a $94.2 million increase, resulting in diluted earnings per share of $8.14 compared to $5.95 Net sales of $759.3 million, increased $88.3 million, or 13.2%, with a slight decrease in volumes Taro`s FY 14 results. EPS

2.42 PM May 28th 2014

sumit1121

New Member

43 Followers

Sun Pharma  

Taro posted spectacular results this time around. Sun Pharma will also post good results tomorrow. Exporters are doing good currently, so it is a good idea to buy sun pharma today, a combination of good results and short covering on expiry can easily take this stock to 600 levels. 580 can be used

1.54 PM May 28th 2014

Explore Moneycontrol

Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.